A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study

BackgroundNon-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPAR α, β/δ and γ, play a central role in the regulation of glucose and lipid metabolism and of the inflammatory and fibrogenic pathways in liver and in other organs that all contribute to NASH pathogenesis. Lanifibranor (IVA337), a panPPAR agonist, by acting on these three different PPAR isotypes, c ombines pharmacological effects that could address the different components of the disease as demonstrated in preclinical models.

Source: Contemporary Clinical Trials - October 6, 2020 Category: Radiology Authors: Francque Sven, Bedossa Pierre, F. Abdelmalek Manal, M. Anstee Quentin, Bugianesi Elisabetta, Ratziu Vlad, Huot-Marchand Philippe, Scherrer Bruno, Junien Jean-Louis, Broqua Pierre, Abitbol Jean-Louis Source Type: research